Verrica Pharmaceuticals Inc. (VRCA) Tops Q4 EPS by 5c

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) reported Q4 EPS of ($0.53), $0.05 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $1.98 million versus the consensus estimate of $941.92 thousand.

For earnings history and earnings-related data on Verrica Pharmaceuticals Inc. (VRCA) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI